Miravant Medical Technologies Inc. Stock

Miravant Medical Technologies is a pharmaceutical research and development company engaged in photodynamic therapy (PDT), a treatment modality based on drugs that respond to light. The drug and light procedures involve three components, the photoselective drugs, light producing devices and light delivery devices. The Company's products have been developed in-house and with outside collaborators and have been used in various clinical and preclinical investigations. Its most advanced drug, PHOTREX, generic name rostaporfin, has completed two Phase III clinical trials for the treatment of wet age-related macular degeneration (AMD). Miravant has branded its version of PDT technology with the trademark PhotoPoint.